Kunena :: Тема: Posted by Gerald on 28.11.2016 19:53:37: stage 4 lung cancer and tarceva (1/2)

Навигация: Главная Форум Главный раздел Сообщество базовых площадокPosted by Gerald on 28.11.2016 19:53:37: stage 4 lung cancer and tarceva

Добро пожаловать, Гость

Форум

Главный раздел

Сообщество базовых площадок

Posted by Gerald on 28.11.2016 19:53:37: stage 4 lung cancer and tarceva

Страница:
1
2

ТЕМА: Posted by Gerald on 28.11.2016 19:53:37: stage 4 lung cancer and tarceva

Posted by Gerald on 28.11.2016 19:53:37: stage 4 lung cancer and tarceva 7 года 5 мес. назад #900

akipk

High Quality - Low Cost Anti-Cancer Drugs

*
A process for the preparation of Erlotinib comprising: a) the reaction of the compound of formula (II) with the compound of formula (III) b) the subsequent treatment with a source of hydrochloric acid in a suitable solvent to give Erlotinib hydrochloride, is described.
Abbas R, Fettner S, Riek M, et al. A drug-drug interaction study to evaluate the effect of rifampicin on the pharmacokinetics of the EGF receptor tyrosine kinase inhibitor, erlotinib, in healthy subjects [abstract no. 548]. 2003 ASCO Annual Meeting [online]. Available from URL: www.asco.org [Accessed 2005 Jul 25]
foodtube.net/profiles/blogs/posted-by-me...58-01-tarceva-cancer
TARCEVA ROCHE 25 MG 30 FILM KAPLI TABLET
psu.kz/index.php?option=com_kunena&view=...d=286&lang=rus#51262
erlotinib oral and omeprazole-sodium bicarbonate oral
Vergote IB, Joly F, Katsaros D, et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study. J Clin Oncol . 2012;30(suppl; abstr LBA5000).
Interaction between erlotinib and coumarin-derived anticoagulants (including warfarin) can lead to increased INR and bleeding; severe and fatal haemorrhage has been reported. 1,2
Previous RCTs ( Mok et al . 2009 ; Maemondo et al . 2010 ; Mitsudomi et al . 2010 ; Fukuoka et al . 2011 ; Zhou et al . 2011 ; Mitsudomi et al . 2012 ; Zhou et al . 2012 ; Han et al . 2012 ; Rosell et al . 2012 ; Inoue et al . 2013 ; Sequist et al . 2013 ; Wu et al . 2013 , 2014 ) did not show any OS benefits for TKIs in patients harbouring EGFR mutations as compared with those undergoing chemotherapy. Other meta-analyses of treatment with TKIs demonstrate only RR and PFS benefits, but no OS benefit, in a population of mixed EGFR-activating mutations ( Lee et al . 2013 ; Haaland et al . 2014 ; Liang et al . 2014 ). Recently, ( Yang et al . 2014. 2015 ) reported on the OS benefits of afatinib, an irreversible TKI in patients with pooled data from LUX-lung 3 ( Sequist et al . 2013 ) and 6 ( Wu et al . 2014 ). Although afatinib is theoretically more effective in inhibiting EGFR signalling than reversible TKIs by forming permanent covalent bonds and irreversibly inhibiting ATP binding at the tyrosine kinase domain ( Kosaka et al . 2011 ), no RCT and meta-analysis has shown that afatinib is superior to gefinitib or erlotinib in OS benefit. The present meta-analysis incorporates not only RCTs of afatinib but also other currently updated RCTs, including reversible TKIs like gefitinib and erlotinib. Our study reveals significant OS benefits of TKI treatment in patients with exon 19 deletions (HR: 0.72, 95 % CI: 0.60–0.88) but not in those with L858R (HR: 1.15, 95 % CI: 0.95–1.39).
The serum concentration of Erlotinib can be increased when it is combined with Prazosin.
"Smar" targeted photosensitizer conjugated with small molecule target-based anticancer drug which has a simple chemical structure and high stability, is a new promising targeted therapeutic strategy. We herein extended this strategy and reported a novel series of zinc(II) phthalocyanine-erlotinib analogue conjugates with different peripheral substituted positions and lengths of the linker. Having erlotinib analogue as the targeting moiety, all conjugates exhibited high specificity and potent affinity to HepG2 cancer cells and kept high photodynamic activity (IC 50 =3.7–16.7 nmol/L). Structure-activity relationships of these conjugates were assessed by investigating their photophysical/photochemical properties, targeting intracellular uptake and in vitro phototoxicity. The results suggested that α -substituted conjugates showed slightly higher photodynamic activity than β -substituted ones. In conclusion, we have developed a series of promising anticancer agents with high tumor selectivity and anticancer activity for targeted photodynamic therapy.
sharabanu.net/forum/su-tyazhnichaem/1584...nib-versus-docetaxel
Erlotinib Tablets Erlocip 150
creativemanufacturing.net/profiles/blogs...16-44-47-tarceva-and
Tarceva está indicado en el tratamiento de pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico tras fallo, al menos, a un tratamiento quimioterápico anterior. Se deberían considerar los factores asociados con el aumento de supervivencia cuando se prescriba Tarceva. No se ha demostrado beneficio en supervivencia u otros efectos clínicamente relevantes del tratamiento en pacientes con tumores EGFR-negativos Ficha EMEA
In clinical trials, these rare side effects of Tarceva were observed:
Gender of people who have Coughing Up Blood when taking Tarceva *:
zheschool3.ru/index.php/forum/razdel-pre...tarceva-rash-on-legs
Erlocip tablets contains erlotinib and its available as. 100 mg & 150 mg tablets
Regarding the research article I had mentioned above www.ncbi.nlm.nih.gov/pubmed/22000696 and the need to consider whether that might have been evaluating erlotinib response in EGFR-unknowns rather than EGFR-negatives, this statement from that abstract makes me think an objective response was seen in 15% of of EGFR-negatives, rather than 15% of EGFR-unknowns: “The ORR was 66.7% in patients with activating EGFR mutations and 14.8% in patients with wild-type EGFR (2P = .006)”
Treatment with erlotinib significantly inhibited H358 xenograft tumor growth.
Phase 3 Study of Erlotinib 100mg or 150mg in Treating EGFR Mutated Patients With Non-small Cell Lung Cancer
Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs target one of the most important pathways in lung carcinogenesis and are able to exploit the phenomenon of ‘oncogene addiction’, with different efficacy according to EGFR gene mutational status in tumor samples. Gefitinib has been approved only for EGFR mutation bearing patients regardless the line of treatment, while erlotinib is also indicated in patients without EGFR mutation who undergo second- or third-line treatment. Some studies evaluated the main differences between these drugs both for direct comparison and to improve their sequential use. In particular, toxicity profile resulted partially different, and these observations may be explained by several molecular and pharmacokinetic features. Therefore, this review integrates preclinical data with clinical evidences of TKIs to guide the optimization of currently available treatments in advanced NSCLC patients.
Erlonat Tablet Drug name. Erlotinib Strength. 100mg & 150mg Packing. Pack of 30 Tablets
Brand Name. Erlonat 150 mg Table
fps-nso.ru/forum/разное/898-posted-by-ra...djuvant-therapy.html
Study BR.21 baseline characteristics and tumor biomarkers by rash: erlotinib arm (% patients)
33 out of every 100 (33%) had erlotinib
Various clinical trials have also demonstrated that combining erlotinib with chemotherapy is feasible in a wide variety of tumours. In previously reported phase I / Ib trials, the MTD of erlotinib with cytotoxic agents ranged from 100 mg day −1 (with capecitabine / docetaxel: Trigo et al . 2003 ; with capecitabine / oxaliplatin: van Cutsem et al . 2003 ; with docetaxel: Mita et al . 2002 ) to 150 mg day −1 (with oxaliplatin / 5-FU: Jones et al . 2003 ). The MTD of erlotinib of 75 mg day −1 in the present trial is lower than in trials with other combinations. This finding may be due to the additive toxicities with docetaxel / carboplatin. Indeed, dose escalation of erlotinib to 150 mg day −1 after chemotherapy suggests that erlotinib is better tolerated as a single agent in this patient setting.
Long term controlled clinical trial studies with Erlotinib suggested that Erlotinib can cause serious side effects, which include:
European Medicines Agency. Tarceva. Summary of Product Characteristics, 3 February 2014. Accessed at www.ema.europa.eu/docs/en_GB/document_li...0618/WC500033994.pdf. [20 Feb 2014].
Gefitinib was metabolized by CYP3A4, CYP3A5, CYP2D6, and CYP1A1, and to a negligible extent by CYP1A2 and CYP1B1 (Fig. 1A ); the formation of O -desmethyl-gefitinib, the major metabolite observed in human plasma (6 ), was mediated by CYP2D6 (Fig. 1C ). The overall metabolism of erlotinib and formation of O -desmethyl-erlotinib (OSI-420), the major metabolite observed in human plasma (4 ), was mediated primarily by CYP3A4, CYP3A5, and CYP1A1, to a lesser extent by CYP1A2 and CYP2D6, and to a negligible extent by CYP1B1 (Fig. 1B and D ).
A trial looking at radiotherapy with erlotinib for lung cancer that has spread to the brain (TACTIC)
www.teplomaster.am/forum/razdel-predlozh...b-manufacturer-india
The serum concentration of Erlotinib can be increased when it is combined with Chlorpropamide.
PCT Publication No. WO 2008/122776 provides processes for the preparation of erlotinib hydrochloride, sulphate, tosylate, and oxalate.
In one embodiment of this aspect, the present invention provides erlotinib maleate monohydrate of Formula II.
Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful. How Tarceva Is Given: Tarceva is given in tablet form to be taken by mouth at least one hour before or two hours after eating. The tablets are supplied in 25mg, 100mg and 150mg strengths. The amount of Tarceva that you will receive depends on many factors, including your general health or other health problems, and the type of cancer or condition being treated. Your doctor will determine your dose and schedule.
No teratogenic effects were observed in rabbits or rats dosed with erlotinib during organogenesis at doses up to 600 mg/m/day in the rabbit (3 times the plasma drug concentration seen in humans at 150 mg/day) and up to 60 mg/m/day in the rat (0.7 times the clinical dose of 150 mg/day on a mg/m basis).
Irinotecan Camptothecin Navitoclax Erlotinib Hydrochloride Antineoplastic Agents, Phytogenic Antineoplastic Agents